Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.09 Insider Own31.45% Shs Outstand39.11M Perf Week1.42%
Market Cap217.30M Forward P/E- EPS next Y-1.35 Insider Trans0.00% Shs Float29.79M Perf Month-17.90%
Income-41.58M PEG- EPS next Q-0.36 Inst Own58.91% Short Float1.39% Perf Quarter-24.47%
Sales16.22M P/S13.40 EPS this Y-36.95% Inst Trans6.00% Short Ratio2.25 Perf Half Y117.39%
Book/sh2.72 P/B1.84 EPS next Y5.98% ROA-22.31% Short Interest0.41M Perf Year87.27%
Cash/sh3.20 P/C1.56 EPS next 5Y10.90% ROE-34.84% 52W Range1.57 - 8.19 Perf YTD29.53%
Dividend Est.- P/FCF- EPS past 5Y-13.31% ROI-26.66% 52W High-38.98% Beta0.58
Dividend TTM- Quick Ratio6.71 Sales past 5Y5.40% Gross Margin86.79% 52W Low217.76% ATR (14)0.48
Dividend Ex-Date- Current Ratio6.71 EPS Y/Y TTM34.31% Oper. Margin-280.14% RSI (14)41.78 Volatility8.95% 9.22%
Employees47 Debt/Eq0.44 Sales Y/Y TTM-22.26% Profit Margin-256.33% Recom1.00 Target Price12.00
Option/ShortYes / Yes LT Debt/Eq0.33 EPS Q/Q-12.98% Payout- Rel Volume0.44 Prev Close4.78
Sales Surprise-49.09% EPS Surprise-14.04% Sales Q/Q-83.38% EarningsMay 03 BMO Avg Volume184.43K Price5.00
SMA20-11.72% SMA50-14.01% SMA20021.69% Trades Volume81,353 Change4.60%
Date Action Analyst Rating Change Price Target Change
Apr-03-24Initiated JMP Securities Mkt Outperform $12
Aug-24-23Initiated Wedbush Outperform $9
Jun-06-23Resumed Jefferies Buy $11 → $12
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
May-03-24 01:53PM
Apr-24-24 10:05AM
Apr-23-24 08:00AM
Apr-15-24 12:00PM
04:30PM Loading…
Apr-05-24 04:30PM
Apr-04-24 04:30PM
Mar-12-24 09:55AM
Mar-07-24 02:52PM
Mar-06-24 08:00AM
Mar-05-24 04:30PM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
07:00AM Loading…
Nov-22-23 07:00AM
Nov-14-23 04:25PM
Nov-03-23 07:00AM
Oct-31-23 09:00AM
Oct-27-23 04:58AM
Sep-27-23 09:00AM
Sep-11-23 04:05PM
Sep-05-23 04:05PM
Aug-24-23 09:57AM
Aug-13-23 08:04AM
Aug-11-23 03:21PM
Aug-10-23 08:25AM
Jun-30-23 06:10AM
Jun-01-23 07:00AM
08:35AM Loading…
May-11-23 08:35AM
May-01-23 07:00AM
Apr-19-23 10:00AM
Mar-23-23 08:25AM
Mar-16-23 07:30AM
Mar-15-23 07:30AM
Feb-24-23 07:30AM
Feb-17-23 05:08AM
Feb-07-23 07:00AM
Jan-20-23 05:16AM
Dec-12-22 10:22AM
Nov-10-22 09:00AM
Nov-07-22 04:05PM
Sep-07-22 07:00AM
Sep-01-22 07:00AM
Aug-15-22 06:45AM
Aug-11-22 07:00AM
Aug-03-22 07:00AM
Jul-05-22 07:54AM
Jun-06-22 04:51PM
May-10-22 07:00AM
Apr-08-22 02:29PM
Apr-07-22 09:25AM
Mar-24-22 07:00AM
Mar-16-22 08:00AM
Mar-15-22 08:00AM
Feb-08-22 08:00AM
Jan-26-22 06:53AM
Jan-05-22 08:00AM
Dec-14-21 04:01PM
Dec-01-21 08:00AM
Nov-10-21 07:00AM
Nov-08-21 08:03AM
Oct-28-21 04:01PM
Oct-27-21 07:30AM
Sep-14-21 08:00AM
Sep-08-21 08:00AM
Aug-19-21 10:57AM
Aug-18-21 07:30AM
Aug-12-21 07:00AM
Jul-30-21 05:03AM
Jun-24-21 07:00AM
Jun-18-21 09:16PM
Jun-15-21 07:00AM
Jun-10-21 07:00AM
May-27-21 07:30AM
May-21-21 07:41PM
Apr-30-21 04:44PM
Apr-29-21 09:19PM
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.